Advertisement

Topics

Latest "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" News Stories

22:45 EDT 26th March 2017 | BioPortfolio

Here are the most relevant search results for "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" found in our extensive news archives from over 250 global news sources.

More Information about Fluorouracil Leukovorin bevacizumab Colorectal Cancer on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Fluorouracil Leukovorin bevacizumab Colorectal Cancer for you to read. Along with our medical data and news we also list Fluorouracil Leukovorin bevacizumab Colorectal Cancer Clinical Trials, which are updated daily. BioPortfolio also has a large database of Fluorouracil Leukovorin bevacizumab Colorectal Cancer Companies for you to search.

Showing "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" News Articles 1–25 of 17,000+

Extremely Relevant

Adjuvant Bevacizumab for Colorectal Cancer?

Adding bevacizumab to capecitabine did not improve survival for patients with stage III or high-risk stage II disease.


Colorectal Cancer: Isofol’s Modufolin Could Change Mainstay Therapy

Decades-long academic and pharma research to improve on the benefits of the 5-fluorouracil and Leucovorin combination in colorectal cancer has...   

Middle-Aged Man With Acute Thrombocytopenia Subsequent to Fluorouracil and Oxaliplatin Chemotherapy for Colorectal Cancer

A 44-year-old patient with a history of stage IIB colorectal cancer at the hepatic flexure, invading the duodenum and pancreas, was initially diagnosed in September 2005 and received modified Whipple surgery and 8 cycles of adjuvant chemotherapy with capecitabine and oxaliplatin every 3 weeks.


Epigenomics alternations and dynamic transcriptional changes in responses to 5-fluorouracil stimulation reveal mechanisms of acquired drug resistance of colorectal cancer cells

Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial

FDA approves bevacizumab with chemotherapy for platinum-sensitive ovarian cancer

The U.S. Food and Drug Administration (FDA) has approved bevacizumab, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by bevacizumab alone, for the treatment of patients with...

Adjuvant Bevacizumab for Operable Gastroesophageal Cancer

Adding bevacizumab to perioperative chemotherapy failed to improve survival.

Colorectal Diseases Biobank links genetics and colorectal cancer

What if your family's DNA could become the blueprint for your very own precise and personalized treatment for colorectal cancer? Or, better yet, what if it could be used to help doctors screen you earlier for the disease, before it has a chance to strike?

Liquid Biopsy and Colorectal Cancer

A liquid biopsy option for potential colorectal cancer patients. Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide, accounting for more than 600,000 deaths each year. When diagnosed early, before cancer has spread, the relative five-year survival rate for CRC is 90%, but only approximately four out of 10 CRC cases [...]

Early detection of colorectal cancer can save lives

Colorectal cancer is the second leading cause of cancer death for men and women in the United States according to the American Cancer Society.

Medical News Today: Colorectal cancer screening initiative shows promise

The Ohio State University have trialed a colorectal cancer screening initiative for relatives of colorectal cancer patients. The results are promising.

Genetic Factors and Colorectal Cancer: Know Your Risk

Colorectal cancer is one of several cancers with known genetic risk factors. Because these known factors can be identified through genetic testing, it’s important to understand your risks and to discuss them with your healthcare provider. The following are three hereditary factors that can increase your risk for colorectal cancer: People with a personal or […] The post Genetic Factors and ...

CHARTA Shows Survival Benefit of Four-Drug Regimen for Advanced CRC

This video examines results of the CHARTA trial, which tested first-line FOLFOX plus bevacizumab with or without irinotecan in patients with advanced colorectal cancer.

Sessile Serrated Polyps and Colorectal Cancer

To the Editor The comprehensive review by Dr Lieberman and colleagues addressed evolving issues in the field of colorectal cancer screening. However, I take issue with the brief discussion of serrated polyps and their effect on the practice of colorectal cancer screening.

Fecal Fat Points to Early Presence of Colorectal Cancer

Colorectal cancer (CRC) remains a leading cause of cancer mortality worldwide, and therefore more accessible screening tests are urgently needed...

Blood Test for Colorectal Cancer Recurrence Proves Highly Sensitive

When diagnosed early, before cancer has spread, the relative five-year survival rate for colorectal cancer (CRC) is 90%, but only...

Technology advances help to prevent, lessen impact of colon cancer

Approximately 140,000 people are diagnosed with colorectal cancer in the U.S. each year. March is Colorectal Cancer Awareness Month.

Colorectal cancer statistics, 2017

(American Cancer Society) Despite dramatic reductions in overall colorectal cancer incidence and mortality, striking disparities by age, race, and tumor subsite remain

Bevacizumab for Extensive-Stage Small-Cell Lung Cancer

Adding bevacizumab to cisplatin and etoposide improved progression-free survival, but not overall survival, the primary outcome.

Metastatic Colorectal Cancer: Does Exercise Matter?

Patients with colorectal cancer may be able to lower the risk of the disease worsening and improve their chances of survival with moderate daily exercise, according to new research by investigators at Dana-Farber Cancer Institute. The results of the research contradict the widespread belief that, because the prognosis for patients with metastatic cancer is often poor, […] The post Metastati...

FDA Approves Avastin® (Bevacizumab) Plus Chemotherapy for Treatment of Advanced Ovarian Cancer

Genentech announced that the U.S. Food and Drug Administration (FDA) has approved Avastin® (bevacizumab) either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Women are said to...

Metabolite that promotes cancer cell transformation and colorectal cancer spread identified

Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial–mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread. The finding highlights the value of targeting D-2HG to establish new therapeutic approaches against...

Dramatic Rise in Colorectal Cancer in Younger Adults

Colorectal cancer rates have risen dramatically among Generation Xers and millenials; researcher warns that repeal of the Affordable Care Act is 'very concerning' for cancer diagnosis. Medscape Medical News

March is Colorectal Cancer Awareness Month: Here are 6 prevention recommendations that confuse association with causation

March is Colorectal Cancer Awareness Month, which the American Institute of Cancer Research is marking with a news release headlined “6 Steps to Prevent Nearly Half of Colorectal Cancer Cases.” The recommendations are said to be “research-based” but that term appears to be used loosely. Here’s why. What’s wrong with issuing sensible lifestyle recommendations? The […]


Quick Search
Advertisement
 

News Quicklinks